Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger pati...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 May 2017
|
| In: |
Blood cancer journal
Year: 2017, Volume: 7, Issue: 5 |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/bcj.2017.45 |
| Online Access: | Verlag, kostenfrei, Volltext: https://www.nature.com/articles/bcj201745 Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1038/bcj.2017.45 
|
| Author Notes: | S. Jaramillo, A. Benner, J. Krauter, H. Martin, T. Kindler, M. Bentz, H. R. Salih, G. Held, C.-H. Köhne, K. Götze, M. Lübbert, A. Kündgen, P. Brossart, M. Wattad, H. Salwender, B. Hertenstein, D. Nachbaur, G. Wulf, H.-A. Horst, H. Kirchen, W. Fiedler, A. Raghavachar, G. Russ, S. Kremers, E. Koller, V. Runde, G. Heil, D. Weber, G. Göhring, K. Döhner, A. Ganser, H. Döhner, R. F. Schlenk |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1578855837 | ||
| 003 | DE-627 | ||
| 005 | 20230427065635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180814s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/bcj.2017.45 |2 doi | |
| 035 | |a (DE-627)1578855837 | ||
| 035 | |a (DE-576)508855837 | ||
| 035 | |a (DE-599)BSZ508855837 | ||
| 035 | |a (OCoLC)1341016892 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Jaramillo Segura, Sonia |e VerfasserIn |0 (DE-588)1149855606 |0 (DE-627)1010162772 |0 (DE-576)496412213 |4 aut | |
| 245 | 1 | 0 | |a Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia |c S. Jaramillo, A. Benner, J. Krauter, H. Martin, T. Kindler, M. Bentz, H. R. Salih, G. Held, C.-H. Köhne, K. Götze, M. Lübbert, A. Kündgen, P. Brossart, M. Wattad, H. Salwender, B. Hertenstein, D. Nachbaur, G. Wulf, H.-A. Horst, H. Kirchen, W. Fiedler, A. Raghavachar, G. Russ, S. Kremers, E. Koller, V. Runde, G. Heil, D. Weber, G. Göhring, K. Döhner, A. Ganser, H. Döhner, R. F. Schlenk |
| 264 | 1 | |c 26 May 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online 26 May 2017 | ||
| 500 | |a Gesehen am 14.08.2018 | ||
| 520 | |a The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival. | ||
| 700 | 1 | |a Benner, Axel |d 1959- |e VerfasserIn |0 (DE-588)106584686X |0 (DE-627)81687221X |0 (DE-576)425536602 |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d [London] : Springer Nature, 2011 |g 7(2017,5) Artikel-Nummer e564, 8 Seiten |h Online-Ressource |w (DE-627)655134174 |w (DE-600)2600560-8 |w (DE-576)339571802 |x 2044-5385 |7 nnas |a Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia |
| 773 | 1 | 8 | |g volume:7 |g year:2017 |g number:5 |g extent:8 |a Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia |
| 856 | 4 | 0 | |u https://www.nature.com/articles/bcj201745 |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/bcj.2017.45 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180814 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 50000 |e 50000PS129025380 |k 0/50000/ |p 33 |y j | ||
| 998 | |g 106584686X |a Benner, Axel |m 106584686X:Benner, Axel |d 50000 |e 50000PB106584686X |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1578855837 |e 3021151035 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 17.07.24"],"pubHistory":["1.2011-"],"language":["eng"],"part":{"volume":"7","year":"2017","issue":"5","extent":"8","text":"7(2017,5) Artikel-Nummer e564, 8 Seiten"},"disp":"Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemiaBlood cancer journal","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"655134174","origin":[{"publisherPlace":"[London] ; London [u.a.]","dateIssuedKey":"2017","dateIssuedDisp":"2017-","publisher":"Springer Nature ; Nature Publ. Group"}],"title":[{"title":"Blood cancer journal","title_sort":"Blood cancer journal"}],"id":{"zdb":["2600560-8"],"eki":["655134174"],"issn":["2044-5385"]},"physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedDisp":"26 May 2017","dateIssuedKey":"2017"}],"title":[{"title_sort":"Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia","title":"Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"8 S."}],"id":{"eki":["1578855837"],"doi":["10.1038/bcj.2017.45"]},"person":[{"family":"Jaramillo Segura","role":"aut","display":"Jaramillo Segura, Sonia","given":"Sonia"},{"family":"Benner","role":"aut","display":"Benner, Axel","given":"Axel"},{"role":"aut","family":"Schlenk","given":"Richard Friedrich","display":"Schlenk, Richard Friedrich"}],"recId":"1578855837","note":["Published online 26 May 2017","Gesehen am 14.08.2018"],"language":["eng"],"name":{"displayForm":["S. Jaramillo, A. Benner, J. Krauter, H. Martin, T. Kindler, M. Bentz, H. R. Salih, G. Held, C.-H. Köhne, K. Götze, M. Lübbert, A. Kündgen, P. Brossart, M. Wattad, H. Salwender, B. Hertenstein, D. Nachbaur, G. Wulf, H.-A. Horst, H. Kirchen, W. Fiedler, A. Raghavachar, G. Russ, S. Kremers, E. Koller, V. Runde, G. Heil, D. Weber, G. Göhring, K. Döhner, A. Ganser, H. Döhner, R. F. Schlenk"]}} | ||
| SRT | |a JARAMILLOSCONDENSEDV2620 | ||